X4 Pharmaceuticals, Inc. (XFOR) Fair Value 2026

XFOR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, X4 Pharmaceuticals, Inc. (XFOR) trades at $4.04, versus a $1.03 median fair value across its 2 active models — 74.6% below the current price. QOC: 6.3/10. Value Trap Risk: 36/100 (LOW). 2/13 models active.

Key Facts

Ticker
XFOR
Price
$4.04
Quality Score
6.3/10
Value Trap Risk
36/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is X4 Pharmaceuticals, Inc. (XFOR) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, X4 Pharmaceuticals, Inc. (XFOR) appears overvalued as of : the median of 2 independent fair value estimates is $1.03, 74.6% below the current price of $4.04. Estimates range from $0.23 to $1.82. XFOR scores 6.3/10 on fundamental quality and 36/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. XFOR’s -74.6% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy X4 Pharmaceuticals, Inc. Stock in 2026? →

What Fair Value Does Each Model Give XFOR?

2 Intrinsic Value Models vs. Current Price ($4.04)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.23 -94.3%
Relative · Low Conviction
 $1.82 -54.8%

All Models Active

All 2 models are displayed above.

What Is X4 Pharmaceuticals, Inc. (XFOR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, X4 Pharmaceuticals, Inc.'s intrinsic value is estimated at $1.03, suggesting the stock is overvalued at its current price of $4.04. With 2 out of 2 models flagging downside (-74.6% vs price), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at -54.8% (fair value: $1.82), while ML-RIV is the most conservative at -94.3% ($0.23). The spread between these extremes — +39.5% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About XFOR?

2 of 13 models are currently active for XFOR. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for XFOR is $1.03 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does XFOR Rank in Biotechnology?

Among 625 Biotechnology stocks, XFOR ranks #121 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, X4 Pharmaceuticals, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is XFOR a Value Trap?

CirclFi's Value Trap algorithm assigns XFOR a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for X4 Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, X4 Pharmaceuticals, Inc. is rated at 6.3/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +39.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every XFOR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across XFOR's 2 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy X4 Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NTLAIntellia Therapeutics, Inc.QOC 6.3EVMNEvommune, Inc.QOC 6.2LXRXLexicon Pharmaceuticals, Inc.QOC 6.3CDXSCodexis, Inc.QOC 6.2PHATPhathom Pharmaceuticals, Inc.QOC 6.3LEXXLexaria Bioscience Corp.QOC 6.2XBITXBiotech Inc.QOC 5.1BCTXBriaCell Therapeutics Corp.QOC 4.6CPMVMosaic ImmunoEngineering, Inc.QOC 3.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NTLA · EVMN · LXRX · CDXS · PHAT · LEXX · XBIT · BCTX · CPMV · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to XFOR?

6 companies across all industries closest to XFOR’s Quality of Company score of 6.3/10.

AHCOAdaptHealth Corp.QOC 6.3UPLDUpland Software, Inc.QOC 6.3AIOTPowerFleet, Inc.QOC 6.3AERGApplied Energetics, Inc.QOC 6.3CPIXCumberland Pharmaceuticals Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AHCO · UPLD · AIOT · AERG · CPIX · NVDA

Where Does XFOR Sit in CirclFi's Biotechnology Rankings?

XFOR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About X4 Pharmaceuticals, Inc.’s Valuation?

What is X4 Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi puts X4 Pharmaceuticals, Inc. (XFOR)'s intrinsic value at $1.03 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.23 to $1.82. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is XFOR overvalued or undervalued right now?

At $4.04, 0 of 2 active models suggest XFOR may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $1.03, 74.6% below the current price of $4.04 — a consensus view that XFOR is overvalued. The assessment depends on which methodology best fits X4 Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for XFOR?

X4 Pharmaceuticals, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on XFOR?

CirclFi analyzes XFOR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is XFOR a value trap in 2026?

X4 Pharmaceuticals, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, X4 Pharmaceuticals, Inc. (XFOR) has a median fair value of $1.03 — 74.6% below the current price of $4.04 — as of 2026-08-28.” Source: circlfi.com/stock/XFOR/ · Methodology
Primary sources for this XFOR valuation
  • Financial statements: X4 Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001501697) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for XFOR as of ; valuations recomputed .